NASDAQ:BCYC Bicycle Therapeutics Q4 2024 Earnings Report $4.15 +0.10 (+2.47%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$4.29 +0.14 (+3.42%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bicycle Therapeutics EPS ResultsActual EPS-$0.75Consensus EPS -$0.85Beat/MissBeat by +$0.10One Year Ago EPS-$1.16Bicycle Therapeutics Revenue ResultsActual Revenue$3.70 millionExpected Revenue$5.47 millionBeat/MissMissed by -$1.77 millionYoY Revenue Growth-30.20%Bicycle Therapeutics Announcement DetailsQuarterQ4 2024Date2/25/2025TimeBefore Market OpensConference Call DateTuesday, February 25, 2025Conference Call Time7:00AM ETUpcoming EarningsBicycle Therapeutics' Q2 2026 earnings is estimated for Friday, August 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Bicycle Therapeutics Earnings HeadlinesBicycle Therapeutics (NASDAQ:BCYC) & Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) Head to Head ContrastJune 5, 2026 | americanbankingnews.comBicycle Therapeutics: Trading Below Cash Amid Multiple UncertaintiesJune 1, 2026 | seekingalpha.comThe Next QualcommPorter Stansberry recommended Qualcomm in 1999 at $4 a share - it climbed more than 5,000%. He found the same tollbooth dynamic in Shopify in 2016, which has risen over 3,500% since. Now he believes he has found his third: a structurally irreplaceable company at the center of a multitrillion-dollar national security buildout backed by more than $3 trillion in public and private capital. A key event this year could accelerate the move. He has also identified four additional stocks positioned to climb before most investors catch on.June 16 at 1:00 AM | Porter & Company (Ad)Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Option Care Health (OPCH)May 31, 2026 | theglobeandmail.comBicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026April 20, 2026 | businesswire.comRBC Capital lowers its price target on Bicycle Therapeutics plc (BCYC) to $7 from $11April 4, 2026 | msn.comSee More Bicycle Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicycle Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicycle Therapeutics and other key companies, straight to your email. Email Address About Bicycle TherapeuticsBicycle Therapeutics (NASDAQ:BCYC) plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology. Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Its oncology portfolio includes targeted agents aimed at tumor-associated receptors and tumor-penetrating ligands designed to deliver therapeutic payloads. In parallel, the company is advancing candidates in neuroscience and immuno-oncology, seeking to address high-unmet-need conditions. Bicycle’s programs are being evaluated in preclinical and early clinical studies, and the company has established research collaborations with several global biopharmaceutical organizations to accelerate the clinical development of its lead molecules. Headquartered in Cambridge, UK, Bicycle Therapeutics has expanded its presence with operations in the United States to support its growing clinical activities and partnerships. The company is led by an experienced management team with deep expertise in peptide chemistry, translational research and drug development. By integrating its proprietary platform with strategic alliances, Bicycle Therapeutics aims to advance a new class of precision medicines capable of reaching challenging therapeutic targets with improved safety and efficacy profiles.View Bicycle Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?3 AI Stocks With Moats That Could Outlast Summer VolatilityViasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on Inflation Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
